Mes: agosto 2020

Body Weight Has Surprising, Scary Impact on Brain Function

COSTA MESA, Calif., Aug. 5, 2020 /PRNewswire/ — As a person’s weight goes up all regions of the brain go down in activity and blood flow in a linear correlation, according to a new brain imaging study in the

COSTA MESA, Calif., Aug. 5, 2020 /PRNewswire/ — As a person’s weight goes up all regions of the brain go down in activity and blood flow in a linear correlation, according to a new brain imaging study in the Journal of Alzheimer’s Disease from researchers at Amen Clinics, the nation’s leader in brain-centered mental health treatment. 

For this study, scientists analyzed over 35,000 brain SPECT scans from more than 17,000 individuals, making this one of the largest studies linking obesity with brain dysfunction. Low cerebral blood flow is the #1 brain imaging predictor that a person will develop Alzheimer’s disease. It is also associated with depression, ADHD, bipolar disorder, schizophrenia, traumatic brain injury, addiction, suicide, and more.

«This study shows that being overweight or obese seriously impacts brain activity and increases the risk for Alzheimer’s disease as well as many other psychiatric and cognitive conditions,» says Daniel G. Amen, MD, the study’s lead author and founder of Amen Clinics.

Considering the latest statistics showing that 72% of Americans are overweight and 42% are obese, this is distressing news for our nation’s mental and cognitive health.

Although the results of this study are concerning, there is hope. The most important lesson learned from treating tens of thousands of patients at Amen Clinics and reviewing over 160,000 brain scans is that you’re not stuck with the brain you have. By adopting brain-friendly habits, such as a healthy diet and regular exercise, you can change your brain and reduce your risk for Alzheimer’s and mental health conditions.

ABOUT AMEN CLINICS
Amen Clinics, Inc. was established in 1989 by Daniel G. Amen, MD, who is a psychiatrist, neuroscientist, and 12-time New York Times bestselling author. Amen Clinics has the world’s largest database of functional brain scans relating to behavior, totaling over 160,000 scans on patients from 155 countries.

Media Contact:
Natalie Buchoz
Amen Clinics
P: (714) 421-3778
E: nbuchoz@amenclinic.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/body-weight-has-surprising-scary-impact-on-brain-function-301107115.html

SOURCE Amen Clinics, Inc.

Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis

EAST HANOVER, N.J., Aug. 5, 2020 /PRNewswire/ — Novartis today announced that The New England Journal of Medicine (NEJM) published the positive results from the ASCLEPIOS I and II studies evaluating the safety and efficacy of ofatumumab (OMB157) 20 mg monthly subcutaneous injections versus teriflunomide 14 mg oral tablets taken once daily in adults with relapsing forms of multiple sclerosis (RMS). Both studies met the primary endpoints where ofatumumab showed a significant reduction in the…

EAST HANOVER, N.J., Aug. 5, 2020 /PRNewswire/ — Novartis today announced that The New England Journal of Medicine (NEJM) published the positive results from the ASCLEPIOS I and II studies evaluating the safety and efficacy of ofatumumab (OMB157) 20 mg monthly subcutaneous injections versus teriflunomide 14 mg oral tablets taken once daily in adults with relapsing forms of multiple sclerosis (RMS). Both studies met the primary endpoints where ofatumumab showed a significant reduction in the number of confirmed relapses, evaluated as the annualized relapse rate (ARR).1

«ASCLEPIOS I and II demonstrate the efficacy and safety of ofatumumab and its potential to become a first-choice treatment option that offers RMS patients the flexibility as they continue to live their lives,» said Krishnan Ramanathan, Neuroscience Global Program Head at Novartis. «Ofatumumab is a testament to our commitment to advance science and investigate potential treatments that reimagine care and address significant unmet needs at all parts of the RMS journey.»

Results from the ASCLEPIOS I and II studies showed that compared with teriflunomide, ofatumumab:

  • Significantly reduced the ARR by 51% (0.11 vs 0.22) and 58% (0.10 vs 0.25) in ASCLEPIOS I and II, respectively (P<.001 in both studies) (primary endpoints)1
  • Showed a relative risk reduction of 34% (P=.002) in 3-month confirmed disability worsening (CDW) and 32% (P=.01) in 6-month CDW in a pre-specified meta-analysis, as defined in ASCLEPIOS (disability-related secondary endpoints)1
  • Showed significant reduction of both gadolinium enhancing (Gd+) T1 lesions with a 97% and 94% relative reduction in ASCLEPIOS I and II, respectively, (both P<.001), and an 82% and 85% relative reduction in new or enlarging T2 lesions in ASCLEPIOS I and II, respectively (both P<.001) (MRI-related secondary endpoints)1
  • Showed superiority in reducing neuroaxonal damage in both studies, as measured by neurofilament light chain (NfL) serum concentrations (biomarker secondary endpoint)1; axonal loss, which begins at disease onset, is a detrimental consequence of central nervous system (CNS) inflammation and is a major determinant of irreversible neurological disability in MS patients2
  • Demonstrated a favorable trend in rate of 6-month confirmed disability improvement (CDI) events but did not reach significance (disability-related secondary endpoint)1
  • Showed the annual rate of brain volume loss was not significantly different (MRI-related secondary endpoint)1
  • Demonstrated an overall safety profile similar to teriflunomide, the frequency of serious infections and neoplasms was similar across both treatment groups. Injection-related reactions, nasopharyngitis, headache, injection-site reaction, upper respiratory tract infection and urinary tract infection were the most commonly observed adverse events with ofatumumab, occurring in ≥10% of patients1

«The ASCLEPIOS studies found that ofatumumab produced a significant reduction in new inflammation, as well as fewer clinical relapses and progression events,» said Professor Stephen L. Hauser, Director of the UCSF Weill Institute for Neurosciences and co-chair of the steering committee for the ASCLEPIOS I and II studies. «Ofatumumab represents a potential new option for RMS patients with greater efficacy compared to teriflunomide, a comparable safety profile, and the convenience of once monthly self-administration without the need for infusions.»

These data will be published in the August 6, 2020 issue of The New England Journal of Medicine.

In February, the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) accepted the company’s Supplemental Biologics License Application (sBLA) and Marketing Authorization Application (MAA), respectively, for ofatumumab for the treatment of relapsing forms of multiple sclerosis in adults. If approved, ofatumumab will be the first B-cell therapy that can be self-administered at home and has the potential to become a first-choice treatment for use in RMS patients.

Regulatory approval for ofatumumab in the US is expected in September 2020 and in Europe by Q2 2021. Novartis is committed to bringing ofatumumab to patients worldwide and additional regulatory filings are currently underway.

About ofatumumab
Ofatumumab (OMB157) is a fully human anti-CD20 monoclonal antibody (mAb) in development for RMS that is self-administered by a once-monthly injection, delivered subcutaneously.1,3 As shown in preclinical studies, ofatumumab is thought to work by binding to a distinct epitope on the CD20 molecule inducing potent B-cell lysis and depletion.4 The selective mechanism of action and subcutaneous administration of ofatumumab allows precise delivery to the lymph nodes, where B-cell depletion in MS is needed, and preclinical studies have shown that it may preserve the B-cells in the spleen.5 Once-monthly dosing of ofatumumab also allows faster repletion of B-cells and offers flexibility.6 Ofatumumab was originally developed by Genmab and licensed to GlaxoSmithKline. Novartis obtained rights for ofatumumab from GlaxoSmithKline in all indications, including RMS, in December 2015.7

About ASCLEPIOS I and II studies
The ASCLEPIOS I and II studies are twin, identical design, flexible duration (up to 30 months), double-blind, randomized, multi-center Phase III studies evaluating the safety and efficacy of ofatumumab 20 mg monthly subcutaneous injections versus teriflunomide 14 mg oral tablets taken once daily in adults with RMS. The ASCLEPIOS I and II studies enrolled 1882 patients with MS, between the ages of 18 and 55 years, with an Expanded Disability Status Scale (EDSS) score between 0 and 5.5.1 The studies were conducted in over 350 sites in 37 countries.8 Ofatumumab demonstrated a significant reduction in ARR by 51% (0.11 vs 0.22) and 58% (0.10 vs 0.25) compared with teriflunomide (P<.001 in both studies) in ASCLEPIOS I and II, respectively (primary endpoint). Ofatumumab also showed a relative risk reduction of 34% (P=.002) in 3-month CDW and 32% (P=.01) in 6-month CDW compared with teriflunomide in a pre-specified meta-analysis, as defined in ASCLEPIOS.1

Ofatumumab showed significant reduction of both Gd+ T1 lesions and new or enlarging T2 lesions. It significantly reduced the mean number of both Gd+ T1 lesions (97% and 94% relative reduction in ASCLEPIOS I and II, respectively, both P<.001) and new or enlarging T2 lesions (82% and 85% relative reduction in ASCLEPIOS I and II, respectively, both P<.001) vs teriflunomide.1 Ofatumumab demonstrated that it lowered neurofilament light chain (NfL) levels in serum at the first assessment at Month 3 compared with teriflunomide. There was no difference in slope of brain volume change from baseline between treatments. In a measure of 6-month confirmed disability improvement (CDI) events, a favorable trend for ofatumumab was seen but this did not reach significance vs teriflunomide.1

Ofatumumab had a similar safety profile to teriflunomide, with the frequency of serious infections and neoplasms also being similar across both treatment groups.1 Injection-related reactions, nasopharyngitis, headache, injection-site reaction, upper respiratory tract infection and urinary tract infection were the most commonly observed adverse events with ofatumumab, occurring in ≥10% of patients.1

Overall, ofatumumab, a fully-human antibody targeting CD20 positive B-cells, delivered superior efficacy and demonstrated a safety profile with infection rates similar to teriflunomide.1

About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by myelin destruction and axonal damage of the brain, optic nerves and spinal cord.9 MS, which affects approximately 2.3 million people worldwide,10 can be characterized into four main types of MS: clinically isolated syndrome (CIS), relapsing remitting (RRMS), secondary progressive (SPMS) and primary progressive (PPMS).11 The various forms of MS can be distinguished based on whether a patient experiences relapses (clearly defined acute inflammatory attacks of worsening neurological function), and/or whether they experience progression of neurologic damage and disability from the onset of the disease.9 

Novartis in Neuroscience
Novartis has a strong ongoing commitment to neuroscience and to bringing innovative treatments to patients suffering from neurological conditions where there is a high unmet need. We are committed to supporting patients and physicians in multiple disease areas, including MS, migraine, Alzheimer’s disease, Parkinson’s disease, epilepsy and attention deficit hyperactivity disorder, and have a promising pipeline in MS, Alzheimer’s disease, spinal muscular atrophy and specialty neurology.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as «potential,» «can,» «will,» «plan,» «may,» «could,» «would,» «expect,» «anticipate,» «look forward,» «believe,» «committed,» «investigational,» «pipeline,» «launch,» or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Dr. Hauser’s statements reflect his professional opinion and not necessarily the views of The Regents of the University of California. Nothing in his statements shall be construed to imply any support or endorsement of Novartis, or any of its products, by The Regents of the University of California.

About Novartis
Located in East Hanover, NJ Novartis Pharmaceuticals Corporation – an affiliate of Novartis – is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis employs about 15,000 people in the United States. For more information, please visit https://www.novartis.us.

Novartis and Novartis US is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews and @NovartisUS at https://twitter.com/NovartisUS.
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library 
For questions about the site or required registration, please contact media.relations@novartis.com.

References

1.

Hauser S, Bar-Or A, Cohen J, et al. Ofatumumab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2020;383(6):546-557. https://www.nejm.org

2.

Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci. 2003;206(2):165–171.

3.

Bar-Or A, Fox E, Goodyear A, et al. Onset of B-cell depletion with subcutaneous administration of ofatumumab in relapsing multiple sclerosis: results from the APLIOS bioequivalence study. Poster presentation at: ACTRIMS; February 2020; West Palm Beach, FL.

4.

Smith P, Kakarieka A, Wallstroem E. Ofatumumab is a fully human anti-CD20 antibody achieving potent B-cell depletion through binding a distinct epitope. Poster presentation at: ECTRIMS; September 2016; London, UK.

5.

Smith P, Huck C, Wegert V, et al. Low-dose, subcutaneous anti-CD20 therapy effectively depletes B-cells and ameliorates CNS autoimmunity. Poster presentation at: ECTRIMS; September 2016; London, UK.

6.

Savelieva M, Kahn J, Bagger M, et al. Comparison of the B-cell recovery time following discontinuation of anti-CD20 therapies. ePoster presentation at: ECTRIMS; October 2017; Paris, FR.

7.

Genmab Press Release: Genmab announces completion of agreement to transfer remaining ofatumumab rights. December 21, 2015. Accessed June 17, 2020. https://ir.genmab.com/static-files/9d491b72-bb0b-4e46-a792-dee6c29aaf7d

8.

Kappos L, Bar-Or A, Comi G, et al. Ofatumumab versus teriflunomide in relapsing multiple sclerosis: baseline characteristics of two pivotal phase 3 trials (ASCLEPIOS I and ASCLEPIOS II). Poster presentation at: ECTRIMS; October 2018; Berlin, Germany.

9.

Guthrie E. Multiple sclerosis: a primer and update. Adv Studies Pharm. 2007;4(11):313-317.

10.

Multiple Sclerosis International Federation. Atlas of MS 2013-Mapping Multiple Sclerosis Around the World. Accessed July 10, 2020. http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf

11.

National MS Society. Types of MS. Accessed May 20, 2020. https://www.nationalmssociety.org/What-is-MS/Types-of-MS

 

Novartis Media Relations

E-mail: media.relations@novartis.com

Eric Althoff

Jamie Bennett

Head, US Corp & Country External Comms,

Director, US Media Relations

Global Media & Corp Communications

+1 862 217 3976

+1 646 438 4335

jamie.bennett@novartis.com

eric.althoff@novartis.com

Novartis Investor Relations

E-mail: investor.relations@novartis.com

Sloan Simpson

+1 862 778 5052

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/novartis-announces-nejm-publication-of-phase-iii-asclepios-trials-demonstrating-superior-efficacy-of-ofatumumab-in-patients-with-relapsing-multiple-sclerosis-301107052.html

SOURCE Novartis

Year-Round Holiday Lights Are A New, Growing Trend This Year for Home-Owners, Reports American Holiday Lights

NAPERVILLE, Ill., Aug. 5, 2020 /PRNewswire-PRWeb/ — American Holiday Lights of Naperville, IL is lifting people’s spirits amid the pandemic. This summer a local holiday lighting company has been lighting up homes in the Chicagoland area. Now, more than ever, people are staying home and want to enjoy their outdoor space by adding new decor such as beautiful outdoor lights.

«It’s a fun and rewarding business,» says Jeff Krall,…

NAPERVILLE, Ill., Aug. 5, 2020 /PRNewswire-PRWeb/ — American Holiday Lights of Naperville, IL is lifting people’s spirits amid the pandemic. This summer a local holiday lighting company has been lighting up homes in the Chicagoland area. Now, more than ever, people are staying home and want to enjoy their outdoor space by adding new decor such as beautiful outdoor lights.

«It’s a fun and rewarding business,» says Jeff Krall, owner of American Holiday Lights, in Naperville, IL. «You get to bring a lot of joy to people all year round.»

Brilliant, vibrant light displays are identified with the holiday season, but as the COVID19 pandemic has been an overshadowing presence people are looking for new and different ways to deal with the constant reminder. American Holiday Lights has seen an increase in their patio and backyard light installations, with many of the families stating that they are not going on vacation this year and wanted to do something fun to bring comfort and cheer to their homes.

«We wanted to do something fun this summer for our kids and all of our plans have been cancelled, so instead we updated our patio and backyard and made it a fun place for our kids to play and hang out. I wanted to add some color and decided to have backyard lights installed, I called American Holiday Lights and they did an excellent job. Now we love sitting outside in the evening, enjoying the new ambiance and the kids love it too!» says M. Anderson, a third year loyal customer.

Holiday lighting outside of December is becoming more and more common, especially with the advancement of RGB LED lights. Homeowners can now use the same strand of lights for various holidays, saving them time from installing the lights and money because they don’t need to buy new light strands in different colors for each season.

«Halloween is the next upcoming holiday that people get excited about and use lights to decorate for all the trick-or-treaters,» Krall says. «The difficult issue with Halloween is that it’s a short window, if a customer wants holiday lights installed for Halloween and then again for Christmas you need to install orange lights and then take them down to install a new color. With bulbs that can change colors, you only need to do the job once.»

Krall says with Halloween ending right around their busy time, he’s been marketing it more.

«If you take the holiday lights down Nov. 1, you can put Christmas lights up immediately and keep the holiday season going,» he says.

Krall says Fourth of July is another well-lit holiday, but it’s not the only one during the summer months.

«We do some LED permanent lighting for commercial properties and they have the ability to change the color any time to match any holiday or promotion,» he says.

While more people are installing lights for the summer and fall holidays, the last two months of the year are still the most popular for holiday lighting and with the holiday season just around the corner, Krall says, «it’s all hands on deck.»

American Holiday Lights is the leading holiday light installation company serving all of Illinois. With specialized training, attention to detail, and the best holiday decorating products on the market, their crew will handle your holiday light installation, and decorating from start to finish. Focusing on residential and commercial holiday lighting, they have worked with local large and small businesses as well as cities and municipalities. American Holiday Lights is a family owned business that has served the western suburbs of Chicago for over 25 years. Visit AmericanHolidayLights.com for more information or to schedule a custom lighting design consultation, light up your home this holiday season.

For more information on our services:
Residential Holiday Lights Installation Services
Commercial Holiday Light Installation Services

 

SOURCE American Holiday Lights

PriceAdvantage Releases Case Study: How Rutter’s Convenience Stores Managed Fuel Pricing During the 2020 Pandemic

COLORADO SPRINGS, Colo., Aug. 5, 2020 /PRNewswire-PRWeb/ — PriceAdvantage, a patented software solution that helps retailers optimize and manage fuel prices, then automatically execute and verify price changes to the POS, pumps, and price signs, announced today a new case study. The case…

COLORADO SPRINGS, Colo., Aug. 5, 2020 /PRNewswire-PRWeb/ — PriceAdvantage, a patented software solution that helps retailers optimize and manage fuel prices, then automatically execute and verify price changes to the POS, pumps, and price signs, announced today a new case study. The case study demonstrates how Rutter’s, a convenience store chain that operates 78 stores throughout Pennsylvania, West Virginia, and Maryland, embraced technology to optimize fuel prices and streamline the price change execution process.

During the 2020 pandemic, Rutter’s, like all fuel retailers, dealt with extraordinary, day-to-day operational hurdles. They had to ensure that both customers and employees were safe, managed in-store inventory demands, and addressed volatile fuel costs, margins, and decreased volumes. PriceAdvantage enables Rutter’s to manage fuel prices and execute price changes anytime – from anywhere – using a laptop or mobile app.

«We are proud to provide Rutter’s with PriceAdvantage software and Skyline Price Signs, a combination that creates a complete fuel pricing ecosystem,» said Chip Stadjuhar, CEO of Skyline Products. «Rutter’s can optimize and execute fuel price changes, and also receive industry-exclusive communication from the Skyline price signs that automatically confirms the price changed successfully and is displayed correctly on the price sign.»

«Using PriceAdvantage, I can quickly react to market movement at my desk and on my mobile phone,» shared Chris Hartman, Rutter’s Director of Fuel and Forecourt. Chris established pricing rules for all of the stores within PriceAdvantage – including considerations for competitors, desired margins, etc. and looks at PriceAdvantage each morning, and throughout the day, to review all of the stores to ensure they are priced appropriately. «Also, PriceAdvantage ensures that the price change process prevents us from having a posted sign price that is lower than the pump price. The combination of PriceAdvantage and Skyline price signs mitigates these issues.»

Read the case study in its entirety.

About PriceAdvantage
PriceAdvantage creates Software to Fuel Your Pricing StrategyTM. Our easy-to-use, highly configurable solution allows fuel marketers to execute their unique fuel pricing strategy faster and more accurately by reducing manual processes and human errors. PriceAdvantage enables customers to make rapid, informed fuel pricing decisions based on their unique business rules, then automatically post new prices to their POS systems, fuel pumps and price signs, and then receive price change confirmation – all in just minutes. PriceAdvantage is singularly focused on fuel pricing software and is a division of a privately held U.S. company, Skyline Products, which produces software solutions and thousands of American-made gas price and transportation signs annually. Learn more at http://www.PriceAdvantage.com.

About Skyline Products
Skyline Products helps convenience stores and fuel retailers differentiate themselves and increase automotive traffic through electronic LED and scroll price signs that are Designed to be Bold, Engineered to Last. Since 1970, Skyline has invested heavily in research and development to create the industry’s most legible and reliable price signs. Fully designed and manufactured in Colorado Springs, CO, Skyline’s industry-exclusive technologies provide superior display feedback, unmatched brightness control, exceptional full-bodied digits, advanced energy efficiency, and military-grade durability. Additionally, Skyline provides customers with price-change confirmation and the most advanced sign diagnostics on the market. Learn more at SkylineProducts.com.

 

SOURCE PriceAdvantage

Kansas Woman Files Lawsuit Against Vrbo’s Travel Insurer

KANSAS CITY, Kan., Aug. 5, 2020 /PRNewswire/ — A Wichita, Kansas, woman has filed a proposed federal class action lawsuit against the company that serves as the Vrbo travel website’s exclusive travel insurance provider. The lawsuit alleges that CSA Travel Protection, the American affiliate of Italy-based Generali Group, has refused to honor its policy and refund more than $3,500 for a properly…

KANSAS CITY, Kan., Aug. 5, 2020 /PRNewswire/ — A Wichita, Kansas, woman has filed a proposed federal class action lawsuit against the company that serves as the Vrbo travel website’s exclusive travel insurance provider. The lawsuit alleges that CSA Travel Protection, the American affiliate of Italy-based Generali Group, has refused to honor its policy and refund more than $3,500 for a properly cancelled booking of a beach house in Rockport, on the Texas Gulf Coast. 

Audra Sanchez made a reservation through Vrbo in May 2020 for the accommodations for her husband and four children for a weeklong vacation, planned for July 24-31. When booking the property, Ms. Sanchez paid more than $250 for a travel insurance coverage plan from CSA. At that time there were no reports of widespread transmission of COVID-19 in the Wichita or Rockport communities, and both state’s governors had lifted stay-at-home orders.

However, on July 13, Ms. Sanchez’s 12-year-old daughter was directly exposed to COVID-19 while playing at a friend’s house. Ms. Sanchez, who has an autoimmune disorder, was immediately concerned and contacted her doctor, who directed the family to conduct a two-week quarantine. The doctor also wrote a letter, which was submitted to CSA along with her trip cancellation claim, requesting that the insurer «release [Ms. Sanchez] from her obligations to her vacation package at this time» because the doctor directed them to quarantine until at least August 1.

CSA responded by email five days later that the claim was being denied, and only offered a refund of her insurance premium.  

«Ms. Sanchez did all the right things, took all the right precautions, and fully expected this company to honor its commitment,» said Tim Sifers of the Kansas City office of the Potts Law Firm, who represents Ms. Sanchez. «These denials by Vrbo’s insurance provider are widespread, and a class action is the most efficient and effective means to gain compensation for those who purchased these policies in good faith, only to be wrongfully denied.»

The case is Audra Sanchez et. al. v. Generali Group et.al., Case 2:20-cv-02380-SAC-TJJ, filed in U.S. District Court for the District of Kansas in Kansas City.  

Media Contact:  
Barry Pound  
800-559-4534  
barry@androvett.com  

Cision View original content:http://www.prnewswire.com/news-releases/kansas-woman-files-lawsuit-against-vrbos-travel-insurer-301107091.html

SOURCE Potts Law Firm

Youth Climate Activism and Environmental Politics Explored in New Season Of Acclaimed Environmental Series EARTH FOCUS from KCET, Link TV and Thomson Reuters Foundation

BURBANK, Calif., Aug. 5, 2020 /PRNewswire-PRWeb/ — KCET, Southern California’s home for award-winning original public media programming, and Link TV, the national independent non-commercial satellite television network, today announced the episode lineup for the new season of Link TV’s acclaimed original environmental series EARTH FOCUS in partnership with the Thomson Reuters Foundation and the Laboratory for Environmental Narrative Strategies (LENS) at

BURBANK, Calif., Aug. 5, 2020 /PRNewswire-PRWeb/ — KCET, Southern California’s home for award-winning original public media programming, and Link TV, the national independent non-commercial satellite television network, today announced the episode lineup for the new season of Link TV’s acclaimed original environmental series EARTH FOCUS in partnership with the Thomson Reuters Foundation and the Laboratory for Environmental Narrative Strategies (LENS) at UCLA. EARTH FOCUS features investigative reports about our changing environment and how it affects people around the world. In the new season, EARTH FOCUS examines the politics of the environment including youth climate activists around the globe, the transition away from coal in South Africa, curbing illegal, poisonous gold mining in Peru, and a feature-length documentary on the environmental politics of the New West. The new season of EARTH FOCUS premieres on Tues., Sept. 8 at 8 p.m. PT on KCET in Southern California, on Wed., Sept. 9 at 9 p.m. ET/PT on Link TV nationwide (DirecTV 375 and DISH Network 9410), and on Sun., Sept. 13 at 3:30 p.m. ET/PT on WORLD Channel, with streaming on kcet.org/earthfocus and linktv.org/earthfocus.

Launched in 2007, EARTH FOCUS is the longest-running investigative environmental news program on U.S. television. The series provides audiences with urgent global environmental coverage on key issues such as endangered species, climate change, environmental health and sustainable practices. With three new episodes focused on international environmental politics co-produced by the Thomson Reuters Foundation and KCET, EARTH FOCUS continues its commitment to educate audiences about the global issues impacting our planet.

This season will conclude with a fourth episode, a special 90-minute documentary, «The New West and the Politics of the Environment,» set to air on Tues. Sept. 29 at 8 p.m. PT on KCET in Southern California and Wed., Sept. 30 at 9 p.m. ET/PT on Link TV nationwide (DirecTV 375 and DISH Network 9410). Co-produced by KCET and LENS at UCLA, this special episode focuses on legendary Nevada Senator Harry Reid, and how he built the foundations of a green new deal in the most unlikely state in America.

The new season of EARTH FOCUS will air as follows (*schedule subject to change):

«The Youth Climate Movement Around the World» – Tues., Sept. 8 on KCET and Wed., Sept. 9 on Link TV
In 2019, sixteen children from across the world including Greta Thunberg filed a historical, global lawsuit petitioning the United Nations Committee on the Rights of the Child to hold five of the world’s leading economic powers accountable for inaction on the climate crisis. All 16 young people are alarmed by the changes they see in their homelands. This episode includes an interview with Greta and in-depth profiles of four of these young environmentalists: Alexandria Villaseñor in California, Carl Smith in Alaska, Ayakha Melithafa in South Africa and Litokne Kabua in the Marshall Islands.

«Coal Mining in South Africa» – Tues., Sept. 15 on KCET and Wed., Sept. 16 on Link TV
South Africa faces a stark reality as the continent’s largest greenhouse gas emitter. More than 80% of power generation comes from coal, with 11 coal power plants turning the province of Mpumalanga into one of the most polluted areas of the world. As the world moves away from fossil fuels and major global investors pull out, renewable energy fights to forge the future. The tension is palpable among the government, coal producers, workers, and the environment in a post-apartheid South Africa facing pressing developmental challenges of unemployment, poverty and inequality.

«The Price of Gold in Peru» – Tues., Sept. 22 on KCET and Wed., Sept. 23 on Link TV
When Peru’s President Martín Vizcarra came to power in 2018, one of his first priorities was to gain control over the devastating outbreak of illegal gold mining operations. In February 2019, the government launched Operation Mercury, a decisive action to shut down an entire town built around an illegal gold mine. This episode follows chief environmental prosecutor Karina Garay as she works with the police, army and navy in destroying illegal mines and arresting miners in protected areas, while retraining illegal miners and persuading them to join the formalized mining operations.

«The New West and the Politics of the Environment»– Tues., Sept. 29 on KCET and Wed., Sept. 30 on Link TV
A quiet, little-known revolution is taking place in American environmental politics in a most surprising place—Nevada. In this feature-length documentary, EARTH FOCUS tells the story of Harry Reid, a politician who grew up in an Old West mining town, saw the possibility of a New West emerging in Nevada and rode that change to power. Reid used power in new ways to settle water wars with respect for Native Americans, protect endangered species and wilderness, and usher in a just transition to renewable energy.

EARTH FOCUS supports Link TV’s mission to connect viewers to the world. Celebrating its 20th anniversary in 2020, Link TV brings Americans closer to people and events beyond our borders. Leveraging its strong relationships with international producers, it has become a place for powerful human stories, high-quality international journalism, documentaries, and scripted dramas. Link TV is a passport for the globally engaged. By conveying diverse perspectives and unfiltered viewpoints, Link TV works to bridge divides and facilitate conversation, understanding, empathy and change on important global topics. Live streaming takes place daily at LinkTV.org/live from 3:00pm-11:00pm Pacific (6:00pm-2:00am Eastern), showing Link TV’s broad range of quality content for free.

The new season of EARTH FOCUS is part of programming focused on this election cycle, where PBS SoCal and KCET explore the past, present and future of our democracy. KCET and PBS SoCal will bring you NewsHour’s unbiased coverage of the conventions and the debates, FRONTLINE’s investigative reports on the candidates and Washington Week’s analysis. All-new KCET Original documentaries will spotlight California’s changing population, values and social movements. Local election coverage both on-air and online at kcet.org and pbssocal.org deciphers and explains the propositions and measures viewers will find on the ballot and how they will impact the city and state.

Join the conversation on social media using #EarthFocus

ACKNOWLEDGEMENTS
EARTH FOCUS is supported by generous institutional funders. The EARTH FOCUS series was created by Raisa Scriabine.

ABOUT KCET
On-air, online and in the community, KCET plays a vital role in the cultural and educational enrichment of Southern and Central California. KCET offers a wide range of award-winning local programming as well as the finest public television programs from around the world. Throughout its 54-year history, KCET has won hundreds of major awards for its local and regional news and public affairs programming, its national drama and documentary productions, its quality educational family and children’s programs, its outreach and community platforms and its website, kcet.org. KCET is a donor-supported community institution. For additional information about KCET productions, web-exclusive content, programming schedules and community events, please visit kcet.org. Select original programming from KCET is also available for streaming on Apple TV, Samsung devices, YouTube, Amazon and Roku platforms. For more information please visit kcet.org/apps. KCET is a content channel of the Public Media Group of Southern California.

ABOUT LINK TV
Founded in 1999, Link TV is an independent viewer-supported media organization dedicated to providing programs that engage and inform its audiences with unique perspectives, and empower them to become involved in the world. Reaching more than 31 million U.S. satellite households nationally (DIRECTV channel 375 and DISH Network channel 9410), Link TV connects American viewers with people at the heart of breaking events, organizations at the forefront of social change and the vibrant cultures of an increasingly global community. Select programming from Link TV is also available for streaming on Apple TV, YouTube and Roku platforms. For additional information about Link TV productions, web-exclusive content and program schedules, please visit linktv.org.

ABOUT THE THOMSON REUTERS FOUNDATION
The Thomson Reuters Foundation is the corporate foundation of Thomson Reuters, the global news and information services company. As an independent charity, registered in the UK and the USA, we work to advance media freedom, foster more inclusive economies, and promote human rights. Through news, media development, free legal assistance and convening initiatives, we combine our unique services to drive systemic change.

ABOUT THE LABORATORY FOR ENVIRONMENTAL NARRATIVE STRATEGIES AT UCLA
The Laboratory for Environmental Narrative Strategies (LENS) is an incubator for new research and collaboration on storytelling, communications, and media. LENS begins with the idea that the environmental, sustainability, and justice challenges that we face are as much cultural and political as they are scientific and technological. At LENS, scholars investigate environmental stories across cultures and contexts, research the impact of environmental media and communications, teach multimedia storytelling, and collaborate to create new environmental narratives.

 

SOURCE KCET

Worldwide Aluminum Composite Panel Industry to 2027 – Key Acquisitions & Mergers

DUBLIN, Aug. 5, 2020 /PRNewswire/ — The «Aluminum Composite Panel – Global Market Outlook (2019-2027)» report has been added to ResearchAndMarkets.com’s…

DUBLIN, Aug. 5, 2020 /PRNewswire/ — The «Aluminum Composite Panel – Global Market Outlook (2019-2027)» report has been added to ResearchAndMarkets.com’s offering.

Research and Markets Logo

The Global Aluminum Composite Panel market accounted for $7.33 billion in 2019 and is expected to reach $14.50 billion by 2027 growing at a CAGR of 8.9% during the forecast period. Increasing demand from end-use industries is the major factor propelling market growth. However, the high repairing cost if broken or dented is likely to inhibit market growth.

Aluminum composite panels are light-weight compound material consisting of two pre-finished aluminium cover sheets heat-bonded to a core made of polyethylene plastic substance. These panels are used broadly as outer surface layer of commercial buildings and corporate houses.

Based on the vehicle type, the passenger cars segment is estimated to have a lucrative growth owing to increasing demand for private vehicles among customers across the globe. With the rapid urbanization and high disposable income, the customer’s preference is shifting towards personal vehicle rather than travelling by public transport. This change will drive the demand of passenger cars, thereby accelerating market growth.

By geography, Asia Pacific is going to have a lucrative growth during the forecast period due to the expansion in the construction industry in developing nations like India, China, Indonesia and Vietnam. In addition to this, the quick rise in the population, growing number of green building and the high demand for affordable house will further boost the growth of the market.

Some of the key players profiled in the Aluminum Composite Panel Market include Guangzhou Xinghe Acp, Interplast, Mitsubishi Chemical Corporation, Mulford Plastic, Rusal, Shanghai Huayuan New Composite Material Co Ltd, Yaret Industrial Group, Alcobond, Alstone, Alstrong Enterprise, Alubond A, Alucoil, Amag Metall, Constellium, Alcoa and Jyi Shyang Industrial Co., Ltd.

What the report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2018, 2019, 2020, 2024 and 2027
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company Profiling with detailed strategies, financials and recent developments
  • Supply chain trends mapping the latest technological advancements

Key Topics Covered:

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Aluminum Composite Panel Market, By Vehicle Type
5.1 Introduction
5.2 Light Commercial Vehicles
5.3 Passenger Cars
5.3.1 Doors
5.3.2 Hoods
5.3.3 Side Panels
5.3.4 Wings

6 Global Aluminum Composite Panel Market, By Coating Type
6.1 Introduction
6.2 Laminating Coating
6.3 Oxide Film
6.4 Polyester (PE)
6.5 Polyethylene
6.6 Polyvinylidene Difluoride (PVDF)

7 Global Aluminum Composite Panel Market, By Composition
7.1 Introduction
7.2 Core Material
7.3 Metal Skin
7.4 Rear Skin
7.5 Surface Coating

8 Global Aluminum Composite Panel Market, By Type
8.1 Introduction
8.2 Antibacterial
8.3 Antistatic
8.4 Fire-resistant

9 Global Aluminum Composite Panel Market, By Application
9.1 Introduction
9.2 Cladding
9.3 Column Cover and Beam Wrap
9.4 Hoarding
9.5 Insulation
9.6 Interior Decoration
9.7 Signage
9.8 Ceilings
9.9 False Ceilings
9.10 Partition

10 Global Aluminum Composite Panel Market, By End User
10.1 Introduction
10.2 Advertising
10.3 Automotive
10.4 Building & Construction
10.5 Transportation
10.6 Packaging
10.7 Railways

11 Global Aluminum Composite Panel Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa

12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies

13 Company Profiling
13.1 Guangzhou Xinghe Acp
13.2 Interplast
13.3 Mitsubishi Chemical Corporation
13.4 Mulford Plastic
13.5 Rusal
13.6 Shanghai Huayuan New Composite Material Co Ltd
13.7 Yaret Industrial Group
13.8 Alcobond
13.9 Alstone
13.10 Alstrong Enterprise
13.11 Alubond A
13.12 Alucoil
13.13 Amag Metall
13.14 Constellium
13.15 Alcoa
13.16 Jyi Shyang Industrial Co., Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/hc2hzi

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/worldwide-aluminum-composite-panel-industry-to-2027—key-acquisitions–mergers-301106811.html

SOURCE Research and Markets

GOJO is Supporting K-12 Schools with PURELL® Products, Education, and Training

AKRON, Ohio, Aug. 5, 2020 /PRNewswire/ — 


GOJO Industries (PRNewsFoto/GOJO Industries)

…

AKRON, Ohio, Aug. 5, 2020 /PRNewswire/ — 

Media Statement
From Carey Jaros, President and CEO, GOJO

Since February, demand for hygiene products – especially hand sanitizer and surface disinfectant – has been exponentially higher than any time in history. As the pandemic has evolved over the past several months, we have continually adapted our response. What started as a rush for products at retailers in February quickly became urgent demand by those on the front lines of the crisis – hospitals, first responders and grocery stores. This summer, the country started reopening to public life, and businesses, restaurants, and other institutions raced to secure PURELL® Hand Sanitizer, PURELL® brand HEALTHY SOAP™, and PURELL® Surface Spray. As we head into the fall, with reopening continuing while at the same time many areas are seeing a resurgence in illness, demand continues to be extraordinary. 

We recognize the immediate and urgent need to provide K-12 schools with safe and effective hand hygiene and surface disinfecting products as they bring children and teachers back into classrooms over the coming weeks. There has been significant media coverage of the FDA’s recent ban of over 100 brands of hand sanitizer for containing toxic ingredients. In line with our GOJO Purpose of Saving Lives and Making Life Better, never have we felt more responsibility to ensure trusted PURELL® products – which are made with only the best raw materials, are always produced in strict compliance with all FDA and EPA requirements, and are rigorously tested for both safety and efficacy – are available in K-12 schools. 

As families shop for back-to-school supplies, we know they may have some difficulty finding PURELL® Hand Sanitizer on store shelves. While we have returned to shipping product to stores and online retailers at more than double 2019 levels, and while these retailers are enforcing limits to how much any one customer can buy, PURELL® Hand Sanitizer is often wiped out as soon as it is restocked. Our investments in manufacturing, including activating more than two-million additional square feet of production space, will allow us to make exponentially more PURELL® products available in stores and online, over the next six months. 

In the meantime, however, GOJO and our distributor partners are actively working directly with as many school districts throughout the country as we can to provide the PURELL® Hand Sanitizer, PURELL® brand HEALTHY SOAP™, and PURELL® Surface Spray they need to reopen with confidence. For example, we have rapidly developed and launched some new solutions designed especially for schools. We are also providing protocols, training materials, and educational content to support schools in maximizing the impact of the products they have available, including when and how these products should be used, and where to place wall-mounted dispensers, floor stands, and tabletop bottles – so sanitizing and washing fit into the normal flow of the school day.

One of our GOJO Guiding Principles has always been «We Do What’s Right for the Long Haul.» Ensuring our children and those who teach and care for them have access to safe and effective hand sanitizer, soap, and clean surfaces has never been more important. We are proud that PURELL® Hand Sanitizer has been the #1 Most Trusted Brand in Hospitals* for decades, and we are committed to bringing that same peace of mind to parents, students, teachers, and staff during these unprecedented times. We will work tirelessly with our distributor partners to outfit as many schools as we can over the coming weeks and months while also building out our manufacturing capacity to support these schools and the communities they serve, into the future.

*52 Week IRI Data ending April 2018; 2017 HPIS Data; Hall & Partners, September 2017 Brand Survey

About GOJO
GOJO, the inventor of PURELL® Hand Sanitizer, is a leading global producer and marketer of skin health and hygiene solutions for away-from-home settings. The broad GOJO product portfolio includes hand cleaning, handwashing, hand sanitizing, skin care formulas, and surface sprays under the GOJO®, PURELL®, and PROVON® brand names. GOJO formulations use the latest advances in the science of skin care and sustainability. GOJO is known for state-of-the-art dispensing technology, engineered with attention to design, sustainability, and functionality. GOJO programs promote healthy behaviors for hygiene, skin care, and compliance in critical environments. GOJO is a family enterprise headquartered in Akron, Ohio, with operations in the United Kingdom, France, Australia, Japan, Mexico, and Canada. Learn more about GOJO.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/gojo-is-supporting-k-12-schools-with-purell-products-education-and-training-301107056.html

SOURCE GOJO

CPSC Posts Recall to its Web Site

WASHINGTON, Aug. 5, 2020 /PRNewswire/ — The CPSC announces today the following recall is posted in cooperation with the firm listed below.  Recalls can be viewed at www.cpsc.gov.

WASHINGTON, Aug. 5, 2020 /PRNewswire/ — The CPSC announces today the following recall is posted in cooperation with the firm listed below.  Recalls can be viewed at www.cpsc.gov.

About the U.S. CPSC
The U.S. Consumer Product Safety Commission (CPSC) is charged with protecting the public from unreasonable risks of injury or death associated with the use of thousands of types of consumer products.  Deaths, injuries, and property damage from consumer product incidents cost the nation more than $1 trillion annually.  CPSC’s work to ensure the safety of consumer products has contributed to a decline in the rate of deaths and injuries associated with consumer products over the past 40 years.

Federal law bars any person from selling products subject to a publicly announced voluntary recall by a manufacturer or a mandatory recall ordered by the Commission.

For lifesaving information:
– Visit CPSC.gov.
– Sign up to receive our e-mail alerts.
– Follow us on Facebook, Instagram @USCPSC and Twitter @USCPSC. 
– Report a dangerous product or a product-related injury on www.SaferProducts.gov .
– Call CPSC’s Hotline at 800-638-2772 (TTY 301-595-7054).
– Contact a media specialist.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cpsc-posts-recall-to-its-web-site-301107051.html

SOURCE U.S. Consumer Product Safety Commission

Center for American Entrepreneurship Joins Coalition of Business & Policy Organizations in Letter Supporting the Recovery Sector Loan Program & Urging Broader Eligibility

WASHINGTON, Aug. 5, 2020 /PRNewswire-PRWeb/ — John R. Dearie, President of the Center for American Entrepreneurship, today issued the following statement regarding a letter to Congressional leadership signed by a coalition of 29 business and policy organizations regarding the small business Recovery Sector Loan program provisions of the Health, Economic Assistance, Liability Protection, and Schools (HEALS) Act.

«The Center for American Entrepreneurship (CAE) is pleased to join our colleagues…

WASHINGTON, Aug. 5, 2020 /PRNewswire-PRWeb/ — John R. Dearie, President of the Center for American Entrepreneurship, today issued the following statement regarding a letter to Congressional leadership signed by a coalition of 29 business and policy organizations regarding the small business Recovery Sector Loan program provisions of the Health, Economic Assistance, Liability Protection, and Schools (HEALS) Act.

«The Center for American Entrepreneurship (CAE) is pleased to join our colleagues at 29 other organizations in a letter sent yesterday to House Speaker Nancy Pelosi, House Minority Leader Kevin McCarthy, Senate Majority Leader Mitch McConnell, and Senate Minority Leader Charles Schumer in support of the small business Recovery Sector Loan program provisions of the HEALS Act, and urging that the program’s eligibility criteria be broadened to include more small businesses, given the severity and prolonged duration of the COVID-19 crisis. CAE thanks our colleagues at the Economic Innovation Group for their leadership in organizing this important letter.

«As the letter states:

‘We strongly affirm that the structure of the proposed lending instrument – i.e., long-term, very low-interest, waived credit tests, and deferred repayment – is the right approach for businesses who need to weather an extended crisis and the resulting decrease in consumer demand. The proposed 7(a) Recovery Sector Loan Program would fill a crucial gap in current support for small businesses, and serve as a necessary complement to existing government-backed options, such as the short-term assistance offered by PPP or the Economic Injury Disaster Loan (EIDL) program.

‘However, as currently drafted, the Recovery Sector Loan Program’s narrowly-defined eligibility requirements would bypass the majority of small businesses desperately in need of a lifeline. To remedy this, we urge Congress to lower the revenue loss threshold below the current 50 percent requirement and shorten the time period during which the revenue loss must have occurred to eight weeks versus one quarter. We also recommend broadening the eligibility to any business who meets the size threshold and economic harm standard, regardless of location. However, we also recognize that low-income communities have been disproportionately affected by both the public health crisis and the resulting economic fallout. Therefore, we would support measures to provide additional targeting to small businesses in these communities in the form of set-asides or streamlined eligibility standards.’

«CAE thanks Speaker Pelosi and Leaders McConnell, Schumer, and McCarthy for their work to date to protect small businesses from the impact of the COVID-19 pandemic. We agree with our colleagues that Congress must now move beyond stop-gap relief and enact a program that more fully aligns with the scale and duration of the crisis. We look forward to working with Congress and the Administration to see the assistance small businesses need and deserve enacted into law.»

The 29 signatories of the letter include: American Hotel & Lodging Association, American Mold Builders Association, America’s Recovery Fund Coalition, Asian American Hotel Owners Association, Center for American Entrepreneurship, Economic Innovation Group, Engine, Exhibitor Appointed Contractor Association, Exhibition Services & Contractors Association, Experiential Design + Producers Association, Go LIVE Together, Gusto, Independent Payroll Providers Association, International Association of Amusement Parks and Attractions, International Association of Exhibitions and Events, International Council of Shopping Centers, International Franchise Association, National Tooling and Machining Association, NFIB, North American Die Casting Association, Page 30 Coalition, Precision Machined Products Association, Precision Metalforming Association, Small Business & Entrepreneurship Council, Small Business for America’s Future, Small Business Majority, Society of Independent Show Organizers, The Payroll Group, and U.S. Travel Association.

The full letter to Congressional leadership can be found here.

About the Center for American Entrepreneurship (CAE)
The Center for American Entrepreneurship (CAE) is a nonpartisan research, policy, and advocacy organization whose mission is to engage and educate policymakers in Washington, and at state and local levels across the nation, regarding the critical importance of entrepreneurs and startups to innovation, economic growth, job creation, and expanding opportunity – and to pursue a comprehensive policy agenda intended to significantly enhance policy circumstances for new business formation, survival, and growth.

For more information, visit StartupsUSA.org

Follow CAE on Twitter: @startupsUSAorg

 

SOURCE Center for American Entrepreneurship